Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Transmedics Group Inc (NQ: TMDX )

140.89 +3.36 (+2.44%)
Streaming Delayed Price Updated: 10:29 AM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Transmedics Group Inc

TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
From The Rosen Law Firm, P.A.
Via Business Wire
New Innovation-Themed Whitepaper to Debut at the February 1st Emerald Groundhog Day Investment Forum
From Emerald Asset Management PA, LLC
Via Business Wire
TransMedics Group Inc. (NASDAQ: TMDX) is a Leading Gainer in 11/7 Morning Trading
Via Investor Brand Network
TransMedics Group Inc. (NASDAQ: TMDX) is a Stock Spotlight on 5/12
Via Investor Brand Network
TransMedics Group Inc. (NASDAQ: TMDX) is a Stock Spotlight on 4/28
Via Investor Brand Network
Investment Opportunities in the Innovation Economy Headline the 2024 Emerald Groundhog Day Investment Forum
From Emerald Asset Management PA, LLC
Via Business Wire
TransMedics Group Inc. (NASDAQ: TMDX) Making Surprising Moves in Friday Session
Via Investor Brand Network
TransMedics to Present at Upcoming March Investor Conferences
From TransMedics
Via GlobeNewswire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. 
Via MarketBeat
Topics ETFs Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.